Biolase, Inc. (BIOL): Price and Financial Metrics
GET POWR RATINGS... FREE!
BIOL Stock Summary
- BIOLASE INC's market capitalization of $4,051,515 is ahead of merely 0.64% of US-listed equities.
- BIOL's price/sales ratio is 0.09; that's higher than the P/S ratio of just 1.37% of US stocks.
- The volatility of BIOLASE INC's share price is greater than that of 96.25% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to BIOL, based on their financial statements, market capitalization, and price volatility, are RWLK, CSPI, ITI, AWH, and HUN.
- BIOL's SEC filings can be seen here. And to visit BIOLASE INC's official web site, go to www.biolase.com.
BIOL Valuation Summary
- In comparison to the median Healthcare stock, BIOL's price/earnings ratio is 100.9% lower, now standing at -0.2.
- Over the past 243 months, BIOL's price/sales ratio has gone down 5.7.
Below are key valuation metrics over time for BIOL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BIOL | 2023-01-30 | 0.1 | 0.3 | -0.2 | -0.4 |
| BIOL | 2023-01-27 | 0.1 | 0.3 | -0.2 | -0.4 |
| BIOL | 2023-01-26 | 0.1 | 0.3 | -0.2 | -0.4 |
| BIOL | 2023-01-25 | 0.1 | 0.3 | -0.2 | -0.4 |
| BIOL | 2023-01-24 | 0.1 | 0.3 | -0.2 | -0.4 |
| BIOL | 2023-01-23 | 0.1 | 0.3 | -0.2 | -0.4 |
BIOL Growth Metrics
- The 4 year price growth rate now stands at -93.95%.
- Its year over year net cashflow from operations growth rate is now at -20.26%.
- Its 4 year cash and equivalents growth rate is now at -52.36%.
The table below shows BIOL's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 46.819 | -24.283 | -24.27 |
| 2022-06-30 | 44.34 | -21.335 | -19.168 |
| 2022-03-31 | 41.239 | -18.232 | -14.265 |
| 2021-12-31 | 39.188 | -16.71 | -16.704 |
| 2021-09-30 | 35.301 | -14.954 | -17.568 |
| 2021-06-30 | 32.309 | -13.464 | -31.649 |
BIOL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BIOL has a Quality Grade of D, ranking ahead of 22.41% of graded US stocks.
- BIOL's asset turnover comes in at 0.622 -- ranking 67th of 186 Medical Equipment stocks.
- TCMD, XENT, and MSA are the stocks whose asset turnover ratios are most correlated with BIOL.
The table below shows BIOL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.622 | 0.330 | -0.489 |
| 2021-03-31 | 0.599 | 0.290 | -0.720 |
| 2020-12-31 | 0.673 | 0.271 | -0.847 |
| 2020-09-30 | 0.775 | 0.368 | -0.933 |
| 2020-06-30 | 0.945 | 0.365 | -1.223 |
| 2020-03-31 | 1.103 | 0.376 | -0.989 |
BIOL Price Target
For more insight on analysts targets of BIOL, see our BIOL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.25 | Average Broker Recommendation | 1.38 (Strong Buy) |
BIOL Stock Price Chart Interactive Chart >
BIOL Price/Volume Stats
| Current price | $0.57 | 52-week high | $10.70 |
| Prev. close | $0.57 | 52-week low | $0.37 |
| Day low | $0.56 | Volume | 398,600 |
| Day high | $0.58 | Avg. volume | 1,031,532 |
| 50-day MA | $0.66 | Dividend yield | N/A |
| 200-day MA | $2.94 | Market Cap | 4.39M |
Biolase, Inc. (BIOL) Company Bio
BIOLASE, Inc.,a medical device company, develops, manufactures, and markets laser systems in dentistry and medicine in the United States and internationally. It offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. The company was founded in 1984 and is based in Irvine, California.
Latest BIOL News From Around the Web
Below are the latest news stories about BIOLASE INC that investors may wish to consider to help them evaluate BIOL as an investment opportunity.
SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsSWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on its team, portfolio, as well as the progress and achievements of its borrower partners. |
Checklist Stock News: BIOLASE, Inc. (NASDAQ:BIOL) Is in red zone with the indicator reading -2.49%Currently, ($BIOL) Constructed a change of -2.49% (Loss, ↓) in a total of its share price and finished it’s trading at 0.60. BIOLASE, Inc., belongs to Healthcare sector and Medical Devices industry. The company’s … The post Checklist Stock News: BIOLASE, Inc. (NASDAQ:BIOL) Is in red zone with the indicator reading -2.49% appeared first on Stocks Equity . |
BIOLASE REJECTS SONENDO'S "PATENTLY ABSURD" CLAIMSBIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser company, today released the following statement in response to the attempt by Sonendo, Inc., through its wholly-owned subsidiary PIPStek LLC (Sonendo), to use patent litigation to try to save Sonendo's diminished position and reputation in the marketplace. |
Roadblocks To A Successful stocks: BIOLASE, Inc. (NASDAQ:BIOL 10.76%), Myovant Sciences Ltd. (NYSE:MYOV -0.02%)There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Roadblocks To A Successful stocks: BIOLASE, Inc. (NASDAQ:BIOL 10.76%), Myovant Sciences Ltd. (NYSE:MYOV -0.02%) appeared first on Stocks Equity . |
Biolase sees Q4 2022 revenue ahead of consensusDental laser maker, Biolase (BIOL) gained in the pre-market trading Wednesday after pre-announcing better-than-expected revenue data for the Q4 and full year 2022. Read the full story here. |
BIOL Price Returns
| 1-mo | -17.67% |
| 3-mo | -63.69% |
| 6-mo | -89.06% |
| 1-year | -94.43% |
| 3-year | -96.26% |
| 5-year | -98.98% |
| YTD | -12.31% |
| 2022 | -93.33% |
| 2021 | -6.41% |
| 2020 | -24.61% |
| 2019 | -44.17% |
| 2018 | -53.95% |
Continue Researching BIOL
Want to see what other sources are saying about Biolase Inc's financials and stock price? Try the links below:Biolase Inc (BIOL) Stock Price | Nasdaq
Biolase Inc (BIOL) Stock Quote, History and News - Yahoo Finance
Biolase Inc (BIOL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...